Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Agios Pharmaceuticals, Inc. AGIO

Healthcare  —  Biotechnology
32.58 (0.32) (0.97%) as of 25 Sep
Market cap
$2.0B
P/E
0.0×
Revenue Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Agios Pharmaceuticals, Inc. (AGIO) Business Profile

Updated before January 2025

Company Overview

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is a leading biopharmaceutical company dedicated to pioneering innovative therapies in the field of cellular metabolism. Founded in 2008 and headquartered in Cambridge, Massachusetts, Agios has established itself as a trailblazer in the development of treatments for genetically defined diseases. The company was co-founded by Dr. Lewis Cantley, a renowned scientist in the field of cancer metabolism, alongside a team of visionary leaders. Agios is led by its CEO, Brian Goff, who brings extensive experience in the biopharmaceutical industry. Under his leadership, the company continues to focus on advancing its mission to transform the lives of patients with rare and genetically defined diseases.

Core Business Segments

Agios Pharmaceuticals operates primarily in the biopharmaceutical sector, with a focus on developing therapies for rare genetic diseases. The company’s core business segments include:

1. Genetically Defined Diseases

Agios is committed to addressing the unmet needs of patients with rare genetic disorders. The company’s flagship product in this category is PYRUKYND® (mitapivat), a first-in-class, FDA-approved therapy for adults with pyruvate kinase (PK) deficiency. PK deficiency is a rare, inherited disorder that affects red blood cell metabolism, leading to chronic hemolytic anemia. PYRUKYND® represents a significant breakthrough in the treatment of this condition.

2. Research and Development (R&D)

Agios invests heavily in R&D to discover and develop novel therapies targeting cellular metabolism. The company’s robust pipeline includes investigational therapies for other rare genetic diseases, such as thalassemia and sickle cell disease. Agios leverages its deep expertise in cellular metabolism to identify and develop innovative treatments that address the root causes of these diseases.

Business Model

Agios Pharmaceuticals operates on a business model centered around innovation, patient-centricity, and strategic partnerships. The company generates revenue primarily through the commercialization of its therapies, such as PYRUKYND®, and through collaborations with other biopharmaceutical companies. Agios integrates its products and services by:

  • Developing First-in-Class Therapies: Agios focuses on creating therapies that address the underlying causes of rare genetic diseases, providing transformative benefits to patients.
  • Collaborative Partnerships: The company collaborates with academic institutions, research organizations, and industry partners to accelerate the development of innovative therapies.
  • Patient Support Programs: Agios offers comprehensive support programs to assist patients in accessing its therapies, ensuring affordability and adherence.

Strategic Direction

Agios Pharmaceuticals is committed to expanding its portfolio of therapies for rare genetic diseases. The company’s strategic priorities include:

  • Pipeline Expansion: Agios aims to advance its pipeline of investigational therapies, with a focus on diseases such as thalassemia and sickle cell disease. The company is conducting clinical trials to evaluate the safety and efficacy of its investigational drugs.
  • Global Market Expansion: Agios is working to expand the availability of its therapies in international markets, ensuring that patients worldwide can benefit from its innovations.
  • Sustainability Goals: The company is dedicated to sustainability and corporate responsibility, integrating environmental, social, and governance (ESG) principles into its operations.
  • Innovation in Cellular Metabolism: Agios continues to invest in cutting-edge research to uncover new therapeutic targets and develop next-generation treatments.

Competitive Landscape

Agios Pharmaceuticals operates in a competitive biopharmaceutical landscape, facing competition from both established players and emerging companies. Key competitors include:

  • Bluebird Bio, Inc.: Focused on gene therapies for rare genetic diseases.
  • Global Blood Therapeutics (GBT): Specializes in treatments for sickle cell disease.
  • Vertex Pharmaceuticals: Develops therapies for cystic fibrosis and other genetic disorders.
  • CRISPR Therapeutics: Pioneers gene-editing technologies for genetic diseases.

Despite the competition, Agios differentiates itself through its deep expertise in cellular metabolism and its focus on rare genetic diseases.

Risk Factors

Agios Pharmaceuticals faces several risks that could impact its business operations and financial performance, including:

  • Market Dependence: The company relies heavily on the success of PYRUKYND® and its pipeline products. Any setbacks in clinical trials or regulatory approvals could affect revenue.
  • Supply Chain Disruptions: Global supply chain challenges could impact the production and distribution of therapies.
  • Regulatory Risks: The biopharmaceutical industry is highly regulated, and changes in regulatory requirements could delay product approvals.
  • Competition: Intense competition from other biopharmaceutical companies could limit market share.
  • Economic Factors: Economic downturns and changes in healthcare policies could affect patient access to therapies.

Recent Developments

Agios Pharmaceuticals has made significant strides in recent years, including:

  • Approval of PYRUKYND®: The FDA approval of PYRUKYND® marked a major milestone for the company, providing a new treatment option for patients with PK deficiency.
  • Pipeline Progress: Agios has advanced its clinical trials for investigational therapies targeting thalassemia and sickle cell disease, with promising preliminary results.
  • Strategic Partnerships: The company has entered into collaborations with leading research institutions to accelerate the development of innovative therapies.
  • Global Expansion: Agios is working to expand the availability of PYRUKYND® in international markets, with regulatory submissions underway in multiple countries.

Investment Considerations

Investors considering Agios Pharmaceuticals should weigh the following strengths and risks:

Strengths

  • Innovative Pipeline: Agios has a robust pipeline of therapies targeting rare genetic diseases, offering significant growth potential.
  • First-Mover Advantage: The approval of PYRUKYND® positions Agios as a leader in the treatment of PK deficiency.
  • Strong Leadership: The company is led by experienced executives with a proven track record in the biopharmaceutical industry.
  • Focus on Unmet Needs: Agios addresses critical unmet medical needs, providing a competitive edge in the market.

Risks

  • Dependence on PYRUKYND®: The company’s financial performance is heavily reliant on the success of PYRUKYND®.
  • Regulatory Challenges: Delays or rejections in regulatory approvals could impact the commercialization of pipeline products.
  • Market Competition: Intense competition from other biopharmaceutical companies could limit growth opportunities.
  • Economic Uncertainty: Changes in healthcare policies and economic conditions could affect patient access to therapies.

Conclusion

Agios Pharmaceuticals, Inc. is a pioneering biopharmaceutical company with a strong focus on rare genetic diseases. The company’s innovative therapies, such as PYRUKYND®, and its robust pipeline position it as a leader in the field of cellular metabolism. While Agios faces challenges such as market dependence and regulatory risks, its commitment to innovation and patient-centricity provides a solid foundation for future growth. With a strategic focus on pipeline expansion, global market penetration, and sustainability, Agios is well-positioned to deliver long-term value to patients and investors alike.